189 related articles for article (PubMed ID: 16227623)
21. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
22. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
23. Glypican4 promotes cardiac specification and differentiation by attenuating canonical Wnt and Bmp signaling.
Strate I; Tessadori F; Bakkers J
Development; 2015 May; 142(10):1767-76. PubMed ID: 25968312
[TBL] [Abstract][Full Text] [Related]
24. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
[TBL] [Abstract][Full Text] [Related]
25. Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface.
Traister A; Shi W; Filmus J
Biochem J; 2008 Mar; 410(3):503-11. PubMed ID: 17967162
[TBL] [Abstract][Full Text] [Related]
26. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling.
Sung YK; Hwang SY; Farooq M; Kim JC; Kim MK
Exp Mol Med; 2003 Aug; 35(4):257-62. PubMed ID: 14508064
[TBL] [Abstract][Full Text] [Related]
27. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation.
Stigliano I; Puricelli L; Filmus J; Sogayar MC; Bal de Kier Joffé E; Peters MG
Breast Cancer Res Treat; 2009 Mar; 114(2):251-62. PubMed ID: 18404367
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene.
Veugelers M; Cat BD; Muyldermans SY; Reekmans G; Delande N; Frints S; Legius E; Fryns JP; Schrander-Stumpel C; Weidle B; Magdalena N; David G
Hum Mol Genet; 2000 May; 9(9):1321-8. PubMed ID: 10814714
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model.
Peters MG; Farías E; Colombo L; Filmus J; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 2003 Jul; 80(2):221-32. PubMed ID: 12908826
[TBL] [Abstract][Full Text] [Related]
30. Current methods for the detection of glypican-3.
Xiao X; Huang Q; Lin X; Zahid KR; Huang X; Liu T; Zeng T
Anal Methods; 2024 Jan; 16(2):152-160. PubMed ID: 38108085
[TBL] [Abstract][Full Text] [Related]
31. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
Zhou S; Parham DM; Yung E; Pattengale P; Wang L
Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
[TBL] [Abstract][Full Text] [Related]
32. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
33. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis.
Pan Z; Chen C; Long H; Lei C; Tang G; Li L; Feng J; Chen F
Mol Med Rep; 2013 Mar; 7(3):969-74. PubMed ID: 23338845
[TBL] [Abstract][Full Text] [Related]
35. Glypican-3 expression is silenced in human breast cancer.
Xiang YY; Ladeda V; Filmus J
Oncogene; 2001 Nov; 20(50):7408-12. PubMed ID: 11704870
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
38. Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma.
Wang D; Gao Y; Zhang Y; Wang L; Chen G
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31160489
[TBL] [Abstract][Full Text] [Related]
39. Glypican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo.
Hartwig S; Hu MC; Cella C; Piscione T; Filmus J; Rosenblum ND
Mech Dev; 2005 Jul; 122(7-8):928-38. PubMed ID: 15925496
[TBL] [Abstract][Full Text] [Related]
40. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
